Dr. Reddy's Laboratories Ltd. 8-2-337, Road No. 3, Banjara Hills, Hyderabad - 500 034, Telangana, India. CIN : L85195TG1984PLC004507 Tel :+91 40 4900 2900 Fax :+91 40 4900 2999 Email :mail@drreddys.com www.drreddys.com

Please find enclosed a Press Release on

"Dr. Reddy's Laboratories received approval for their NDA, ELYXYB (celecoxib oral solution) 25 mg/mL, in the U.S.."

This is for your information.

CC:- New York Stock Exchange Inc.(Stock Code: RDY)

Classification | PUBLIC

Laboratories received approval for their NDA, ELYXYB

solution) 25 mg/mL, in the U.S.

Hyderabad, India and Princeton, NJ,

USA., May 6, 2020 - Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together

referred to as "Dr. Reddy's") today announced approval of ELYXYB (celecoxib oral solution 25 mg/mL) by the U.S.

Food and Drug Administration (USFDA). ELYXYB (previously known as DFN-15) is indicated for the acute treatment of migraine with

or without aura in adults. ELYXYB is the latest product emerging from Dr. Reddy's portfolio of successful acute migraine

treatments. The company is working to commercialize this product through partners.

Erez Israeli, CEO of Dr. Reddy's Laboratories, commented,

"We are excited about the approval of ELYXYB. It reaffirms our commitment to innovation and to develop meaningfully differentiated

products that address significant unmet needs of patients and physicians, leading to better health outcomes."

According to Anil Namboodiripad, PhD, Sr. Vice President of

the Proprietary Products Group, Dr. Reddy's Laboratories, "ELYXYB is an oral solution of celecoxib formulated using

a self-micro emulsifying drug delivery system that improves solubility and bioavailability of the drug leading to better absorption1.

This allows for administration of a lower dose without affecting bioavailability. In pivotal studies, ELYXYB demonstrated a rapid

onset of action which is critically important to patients suffering from acute migraine attacks. The results from pivotal studies

with ELYXYB established efficacy of celecoxib in the treatment of migraine with very few adverse events. For patients who suffer

from the debilitating and disruptive effects of migraine, there continues to be a need for reliable and efficacious treatment options.

ELYXYB's oral solution dosage form makes it convenient for patients to take it immediately upon emergence of migraine attacks."

INDICATION AND USAGE

ELYXYB is indicated in adults for the acute treatment of migraine

with or without aura.

IMPORTANT SAFETY INFORMATION:

RISK OF SERIOUS CARDIOVASCULAR AND GASTROINTESTINAL EVENTS

Cardiovascular Thrombotic Events

Gastrointestinal Bleeding, Ulceration, and Perforation

ELYXB is contraindicated in patients with:

To minimize the potential risk for an adverse cardiovascular

(CV) event in NSAID-treated patients, use ELYXYB for the fewest number of days per month as needed, based on individual treatment

goals. Physicians and patients should remain alert for the development of such events, throughout the entire treatment course,

even in the absence of previous CV symptoms. Patients should be informed about the symptoms of serious CV events and the steps

to take if they occur.

Avoid the use of ELYXYB in patients with a recent myocardial

infarction (MI) unless the benefits are expected to outweigh the risk of recurrent CV thrombotic events. If ELYXYB is used in patients

with a recent MI, monitor patients for signs of cardiac ischemia.

NSAIDs, including ELYXYB, can cause serious gastrointestinal

(GI) adverse events including inflammation, bleeding, ulceration, and perforation of the esophagus, stomach, small intestine, or

large intestine, which can be fatal. These serious adverse events can occur at any time, with or without warning symptoms, in patients

treated with celecoxib. Only one in five patients who develop a serious upper GI adverse event on NSAID therapy is symptomatic.

Upper GI ulcers, gross bleeding, or perforation caused by NSAIDs occurred in approximately 1% of patients treated for 3 to 6 months,

and in about 2% to 4% of patients treated for one year. However, even short-term NSAID therapy is not without risk.

Avoid the use of ELYXYB in patients with severe heart failure

unless the benefits are expected to outweigh the risk of worsening heart failure. If ELYXYB is used in patients with severe heart

failure, monitor patients for signs of worsening heart failure.

Elevations of ALT or AST (less than three times ULN) may occur

in up to 15% of patients treated with NSAIDs, including ELYXYB.

Long-term administration of NSAIDs, including celecoxib, the

active ingredient in ELYXYB, has resulted in renal papillary necrosis and other renal injury.

No information is available from controlled clinical studies

regarding the use of celecoxib in patients with severe renal impairment. The renal effects of celecoxib may hasten the progression

of renal dysfunction in patients with preexisting renal disease.

Overuse of acute migraine drugs (e.g., ergotamine, triptans,

opioids, nonsteroidal anti-inflammatory drugs or combination of these drugs for 10 or more days per month), including ELYXYB, may

lead to exacerbation of headache (medication overuse headache). Medication overuse headache may present as migraine-like daily

headaches or as a marked increase in frequency of migraine attacks. Detoxification of patients, including withdrawal of the overused

drugs and treatment of withdrawal symptoms (which often includes a transient worsening of headache) may be necessary.

NSAIDs, including ELYXYB, may increase the risk of bleeding

events. Co-morbid conditions such as coagulation disorders or concomitant use of warfarin, other anticoagulants, antiplatelet drugs

(e.g., aspirin), SSRIs, and serotonin norepinephrine reuptake inhibitors (SNRIs) may increase this risk.

Most common adverse reaction (at least 3% and greater than placebo)

These are not all the side effects associated with ELYXYB.

Please see Patient Information, Instructions For Use, Medication

Guide and Full Prescribing Information for ELYXYB.

You are encouraged to report negative side effects of prescription

drugs. To report SUSPECTED SIDE EFFECTS, call Promius Pharma at 1-888-966-8766 or contact the FDA at 1-800-FDA-1088 (1-800-332-1088)

or online at http://www.fda.gov/Safety/MedWatch

About Dr. Reddy's: Dr. Reddy's

Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) is an integrated pharmaceutical company, committed to providing affordable

and innovative medicines for healthier lives. Through its three businesses - Pharmaceutical Services & Active Ingredients,

Global Generics and Proprietary Products - Dr. Reddy's offers a portfolio of products and services including APIs,

custom pharmaceutical services, generics, biosimilars and differentiated formulations. Our major therapeutic areas of focus are

gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Dr. Reddy's operates in markets

across the globe. Our major markets include - USA, India, Russia & CIS countries, and Europe. For more information,

log on to: www.drreddys.com

Disclaimer: This press release may include

statements of future expectations and other forward-looking statements that are based on the management's current views and

assumptions and involve known or unknown risks and uncertainties that could cause actual results, performance or events to differ

materially from those expressed or implied in such statements. In addition to statements which are forward-looking by reason of

context, the words "may", "will", "should", "expects", "plans", "intends",

"anticipates", "believes", "estimates", "predicts", "potential", or "continue"

and similar expressions identify forward-looking statements. Actual results, performance or events may differ materially from those

in such statements due to without limitation, (i) general economic conditions such as performance of financial markets, credit

defaults , currency exchange rates , interest rates , persistency levels and frequency / severity of insured loss events (ii) mortality

and morbidity levels and trends, (iii) changing levels of competition and general competitive factors, (iv) changes in laws and

regulations and in the policies of central banks and/or governments, (v) the impact of acquisitions or reorganization, including

related integration issues, (vi) the susceptibility of our industry and the markets addressed by our, and our customers',

products and services to economic downturns as a result of natural disasters, epidemics, pandemics or other widespread illness,

including coronavirus (or COVID-19), and (vii) other risks and uncertainties identified in our public filings with the Securities

and Exchange Commission, including those listed under the "Risk Factors" and "Forward-Looking Statements" sections

of our Annual Report on Form 20-F for the year ended March 31, 2019.

The company assumes no obligation to update any information

1 Arindam Pal, Srinivas Shenoy, Anirudh Gautam, Sagar